bioRxivImmunologyPreprint
Rational Design of Immunogenic Nanoparticles as a Platform for Enhanced Ovarian Cancer Immunotherapy in Mice
Lien TangiD, Benjamin R MarwedeliD, C.Y. DangiD, Marian OlewineiD, Melanie S. JuniD, Paulina M. Naydenkov, Lorél Y. Medina, Veronica Gayoso, Ngoc Doan, Shamus L O'Leary, Carmine Schiavone, Joseph CaveiD, Tamara A. HowardiD, John D. WattiD, Prashant DograiD, Rita Elena SerdaiD, Achraf NoureddineiD
Abstract
Ovarian cancer immunotherapy remains a challenge based on the "cold" tumor microenvironment. Herein we present a rational design to create immunogenic nanoparticles as a multi-agent platform that promotes immune response in a mouse model of ovarian cancer. The hybrid lipid-silica nanosystem is capable of co-loading four types of cargo molecules including a model antigen, nucleic acid-based adjuvant Cytosine-p-linked to Guanine (CpG, TLR3/9 agonist), lipid-based adjuvant (MPLA, TLR4 agonist) integrated into the lipid coat, and optionally a small molecule drug, such as the chemotherapeutic agent oxaliplatin, a well-established treatment for ovarian cancer. The optimization of the nanoplatform in terms of lipid composition, functionalized silica dendritic core formation, and final charge, as well as their compatibility with the complex loading profile highlights an opportunity for enhanced survival of mice with advanced ovarian cancer compared to monotherapy. Furthermore, intraperitoneal administration led to preferential accumulation within tumor-burdened tissues with selective accumulation in myeloid cells. High myeloid cell cytotoxicity negated the benefits of oxaliplatin. The inclusion of CpG in the nanoparticle formulation enhanced the survival of mice with ovarian cancer. To interpret these outcomes and guide future design, we also developed a mathematical model of nanoparticle-driven immune activation, which quantified treatment efficacy and identified key parameters governing tumor response. The presented hybrid nanoparticle i tunable, enabling delivery of alternative molecules therefore, thereby highlighting a promising platform for the treatment of peritoneal cancers. Graphical TOC O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=69 SRC="FIGDIR/small/657862v1_ufig1.gif" ALT="Figure 1000"> View larger version (26K): org.highwire.dtl.DTLVardef@1434599org.highwire.dtl.DTLVardef@18e79e6org.highwire.dtl.DTLVardef@e5285corg.highwire.dtl.DTLVardef@bcc604_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- 'Target-and-release' nanoparticles for effective immunotherapy of metastatic ovarian cancer
Ivan Susin Pires, Gil Covarrubias, … Paula Therese Hammond·Nature MaterialsPeer-reviewed·Oct 31, 2025
- Hyaluronic Acid-Modified Mesoporous Manganese Dioxide Combined with Carboplatin Synergistically Enhances Ovarian Cancer Therapy
Yong Wang, Jie Pi, … Qingzhen Xie·Journal of Drug Delivery Science and TechnologyPeer-reviewed·Jan 2, 2026
- Development of 3-in-1 nanotherapeutic strategies for ovarian cancer
Emma Durocher, Sean McGrath, … Suresh Gadde·bioRxiv·Jul 17, 2024
- Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy
Victoria F. Gomerdinger, Cassandra Parada, … Paula Therese Hammond·bioRxiv·Jun 25, 2026
- Immunotherapy for ovarian cancer is improved by tumor targeted delivery of a neoantigen surrogate
L. R. Scanlon, L. Gabor, … C. Gravekamp·bioRxiv·Oct 11, 2023
- Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer
L. Wang, J. C. Evans, … C. Allen·bioRxiv·Aug 29, 2022